| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥20.1B | ¥15.7B | +28.3% |
| Operating Income | ¥-14.2B | ¥0.9B | -1599.0% |
| Ordinary Income | ¥-14.8B | ¥0.3B | -5016.7% |
| Net Income | ¥-30.3B | ¥-0.2B | -18856.2% |
| ROE | -414.3% | -0.4% | - |
FY2025 consolidated results show severe operational deterioration with Revenue 20.1B (+28.3% YoY from 15.7B) contrasting sharply against Operating Loss -14.2B (prior year profit 0.9B, -1599.0% YoY), representing a fundamental shift from revenue up/profit up to revenue up/profit down pattern. Ordinary Loss expanded to -14.8B (prior 0.3B, -5016.7% YoY) and Net Loss reached -30.3B (prior -0.2B, -18856.2% YoY). The primary driver was extraordinary impairment loss of 15.1B combined with elevated SGA expenses of 20.0B (99.3% of revenue) and goodwill amortization of 4.0B. Operating margin deteriorated from +6.1% to -70.8% (-76.9pt deterioration). Total Assets contracted from 46.5B to 18.2B with Equity declining from 37.4B to 7.3B as Retained Earnings plunged from 0.3B to -30.5B. Operating CF remained negative at -2.2B (improved from -3.7B prior year) while Free CF was -6.8B. Cash position decreased 84.8% from 6.4B to 1.0B, creating acute liquidity concerns given current ratio of 74.2% and short-term debt coverage of 0.38x. The company faces immediate refinancing risk with 52% short-term liability ratio and goodwill of 19.2B exceeding total equity, indicating substantial impairment risk remains.
Revenue increased 28.3% to 20.1B driven primarily by the Commercial Support Robot Segment which contributed 10.2B (52.4% of total revenue, +162.3% YoY). The Substrate Segment contributed 6.1B (-17.3% YoY), Semiconductor Processing Segment 2.3B (-32.4% YoY), and Real Estate Rent Segment 0.9B (-7.0% YoY). Customer concentration is notable with top three customers representing Sanei Kaken (5.3B, robot segment), Yoshino Trading (3.9B, robot segment), and Sharp Corporation (3.6B, substrate segment) collectively accounting for substantial revenue. Gross profit was 5.7B (28.5% margin, -66.8pt from prior 27.1%) but was overwhelmed by SGA expenses of 20.0B including goodwill amortization of 4.0B, resulting in operating loss of -14.2B. Non-operating expenses of 0.8B (primarily interest 0.1B and commission fees 0.1B) widened ordinary loss to -14.8B. The critical factor was extraordinary loss of 15.8B dominated by impairment loss of 15.1B, driving pre-tax loss to -30.6B and net loss to -30.3B after minimal tax expense of 0.3B. The massive gap between operating loss (-14.2B) and net loss (-30.3B) stems from the 15.1B impairment charge, classified as non-recurring. This represents a revenue up/profit down pattern where top-line growth in the robot business failed to translate into profitability due to excessive fixed cost structure and asset impairment recognition.
The Substrate Segment generated revenue of 6.1B (-17.3% YoY) with operating income of 0.6B (-81.2% YoY) and margin of 9.5%, representing the most profitable segment despite significant margin compression. The Real Estate Rent Segment delivered revenue of 0.9B (-7.0% YoY) with operating income of 0.7B (+8.5% YoY) and exceptional margin of 77.4%, indicating stable asset-light cash generation. The Commercial Support Robot Segment, now the core business at 52.4% revenue share, recorded revenue of 10.2B (+162.3% YoY) but operating loss of -0.2B (prior year loss -0.1B, -137.5% deterioration) with negative margin of -2.4%, highlighting severe scaling challenges. The Semiconductor Processing Segment showed revenue of 2.3B (-32.4% YoY) with operating loss of -0.2B (prior year loss -0.0B, -171.4%) and margin of -6.8%. Unallocated corporate costs of -15.4B significantly depressed consolidated operating income. The robot segment's dominance in revenue without profitability, combined with double-digit declines in the substrate and semiconductor segments, reveals fundamental business model execution risk. The 52.4% concentration in an unprofitable segment creates material vulnerability to further robot business deterioration.
[Profitability] ROE deteriorated to -414.3% (prior 1.6%) reflecting negative equity returns from massive net loss. Operating margin collapsed to -70.8% (prior 6.1%, -76.9pt deterioration). EBITDA margin was -68.3% with EBITDA of -13.7B. Gross margin remained relatively stable at 28.5% versus prior 27.1%, but SGA ratio surged to 99.3% of revenue from prior 21.0%, driven by goodwill amortization (4.0B) and fixed overhead. [Cash Quality] Operating CF/Net Income ratio was 0.07x indicating minimal cash conversion of reported losses. Operating CF improved to -2.2B from prior -3.7B (+39.7% improvement) but remains negative. Free CF was -6.8B with CapEx of 3.5B representing 6.68x depreciation expense of 0.5B, signaling aggressive investment despite negative operating cash generation. Cash conversion rate (Operating CF/Revenue) was -10.9%. [Investment Efficiency] Total asset turnover was 1.10x. CapEx intensity (CapEx/Revenue) reached 17.3%, reflecting heavy investment phase. Goodwill of 19.2B represents 262.6% of equity and 105.5% of total assets, creating substantial impairment overhang. [Financial Health] Equity ratio decreased sharply to 40.2% from 80.3% prior year as equity declined from 37.4B to 7.3B. Current ratio of 74.2% signals liquidity stress with current assets of 5.4B insufficient to cover current liabilities of 7.3B. Quick ratio stood at 65.8%. Interest coverage was -103.02x. Debt-to-equity ratio was 1.49x with total liabilities of 10.9B. Short-term debt coverage (cash/short-term debt) was critically low at 0.38x with cash of 1.0B versus short-term debt of 2.5B (short-term loans payable 0.3B plus current portion of long-term loans 0.2B). Short-term liability ratio reached 52%, indicating acute refinancing risk. Net debt position cannot sustain current burn rate without external funding.
Operating CF of -2.2B improved 39.7% from prior -3.7B but remains deeply negative, representing only 0.07x of net income and indicating poor earnings quality. The subtotal before working capital changes was -2.0B, with working capital contributing -0.2B as inventory decreased by 0.4B (positive impact), receivables decreased by 3.1B (positive impact), but payables decreased by 0.2B (negative impact). Depreciation and amortization of 0.5B and impairment of 1.5B added back to operating CF had limited offsetting effect. Income taxes paid were minimal at -0.2B. Investing CF was -4.5B dominated by CapEx of -3.5B and intangible asset purchases of -0.7B (goodwill decreased from 19.2B prior to 19.2B current, reflecting amortization of 4.0B). Financing CF was positive 1.3B, driven by proceeds from stock issuance of 1.4B and increase in short-term loans of 0.5B, partially offset by long-term loan repayment of -0.2B and lease repayments of -0.0B. The net result was cash decrease of -5.4B, bringing cash and deposits from 6.4B to 1.0B (-84.8%). Free CF of -6.8B indicates severe capital consumption with the CapEx-to-depreciation ratio of 6.68x unsustainable without addressing operating cash deficits. The 0.38x cash coverage of short-term liabilities and 52% short-term liability ratio present immediate liquidity and refinancing risk requiring urgent capital structure adjustment.
Operating income of -14.2B versus ordinary income of -14.8B shows net non-operating contribution of approximately -0.6B, composed of non-operating income 0.3B (primarily dividend income 0.0B and other 0.1B) less non-operating expenses 0.8B (interest 0.1B, commission fees 0.1B, and other 0.1B). Non-operating items represented -3.1% of revenue and are relatively minor compared to operating performance. The primary earnings quality concern is the extraordinary impairment loss of 15.1B (75.2% of revenue) which is non-recurring in nature but reflects underlying business model or acquisition integration issues. The impairment, combined with goodwill amortization of 4.0B (19.9% of revenue), indicates substantial value destruction post-acquisition. Comprehensive income of -30.8B closely tracked net income of -30.3B with minimal other comprehensive income (valuation difference on securities of 0.0B). The 49.5% ratio of non-recurring items to total losses suggests that excluding the 15.1B impairment, underlying operating loss would be approximately -15.2B, still deeply negative. Operating CF of -2.2B falls far short of covering net loss, reflecting the impairment's non-cash nature but also indicating ongoing operational cash consumption. Earnings quality is severely compromised by the combination of operational unprofitability (negative operating margin of -70.8%), excessive SGA burden (99.3% of revenue), and asset impairment recognition signaling prior overpayment or integration failure.
No explicit full-year forecast figures are provided beyond dividend forecast of 0.00. Progress rate analysis cannot be conducted due to absence of revenue and profit guidance. The forecast notes state that forward-looking statements are based on information and reasonable assumptions available to the company, with actual results potentially differing materially due to various factors. Given the severe loss incurred (-30.3B net loss) and operational cash consumption (-2.2B operating CF), lack of quantitative guidance suggests management is assessing strategic alternatives or restructuring scenarios rather than providing normal course projections. The absence of guidance combined with acute liquidity constraints (cash 1.0B, current ratio 74.2%) and large goodwill balance (19.2B) indicates heightened uncertainty around forward business trajectory. Order backlog data is not disclosed, limiting visibility into Commercial Support Robot Segment pipeline despite its 52.4% revenue concentration. The 6.68x CapEx-to-depreciation ratio and -6.8B free cash flow indicate investment-led strategy that cannot be sustained without either operational turnaround or capital raise, neither of which is explicitly guided.
Annual dividend is zero for both H1 and year-end, continuing the no-dividend policy from prior year. Payout ratio is not applicable given net loss of -30.3B. With FCF of -6.8B and negative operating CF of -2.2B, there is no capacity for shareholder distributions. Share buyback activity is minimal with treasury stock purchase of -0.0B (4,000 yen). Total shareholder return ratio cannot be calculated due to absence of positive distributable cash flow. The cash position of 1.0B against short-term liabilities of 7.3B leaves no room for discretionary capital allocation to shareholders. Resumption of dividends would require (1) return to operating profitability, (2) positive operating cash flow generation, (3) restoration of equity base eroded by -30.5B retained earnings deficit, and (4) refinancing or reduction of near-term debt obligations. Under current financial stress with equity ratio declining from 80.3% to 40.2% and cash declining 84.8%, dividend resumption is not feasible in the near term. Priority must be liquidity preservation, cost structure rationalization, and restoration of segment-level profitability before any capital returns to shareholders can be considered.
Business concentration risk: Commercial Support Robot Segment represents 52.4% of revenue with negative operating margin of -2.4% and operating loss of -0.2B. Further deterioration in this core segment would materially impact consolidated results. Customer concentration is evident with Sanei Kaken, Yoshino Trading, and Sharp collectively representing a substantial portion of sales, exposing the company to customer-specific demand volatility or credit risk.
Liquidity and refinancing risk: Current ratio of 74.2% with cash of 1.0B covering only 0.38x of short-term debt (2.5B comprised of short-term loans 0.3B and current portion of long-term loans 0.2B) creates acute near-term funding pressure. The 52% short-term liability ratio indicates over half of total liabilities mature within one year, requiring successful refinancing amid operational losses. Cash decreased 84.8% YoY from 6.4B to 1.0B while operating CF remained negative at -2.2B and FCF was -6.8B, indicating ongoing cash burn that cannot be sustained without external capital injection or dramatic operational improvement.
Goodwill and asset impairment risk: Goodwill of 19.2B represents 262.6% of equity (7.3B) and 105.5% of total assets (18.2B). The recognition of 15.1B impairment loss in the current period signals prior overvaluation or integration challenges, and the remaining goodwill balance remains vulnerable to further impairment if business performance (particularly the robot segment acquired through M&A) fails to meet projections. Additional impairment would further erode equity and potentially trigger debt covenant violations or raise going concern questions given the already negative retained earnings of -30.5B.
[Industry Position] (Reference - Proprietary Analysis)
The company operates across diversified segments including substrate manufacturing, semiconductor processing, real estate rental, and commercial support robotics, making direct peer comparison challenging. However, benchmarking against a composite of manufacturing and technology service companies provides context. Profitability: ROE of -414.3% is substantially below industry median (estimated 8-12% for profitable manufacturing peers) reflecting the extraordinary loss year. Operating Margin of -70.8% contrasts starkly with industry median of 5-15% for manufacturing and technology service sectors, indicating severe operational distress. Financial Health: Equity Ratio of 40.2% is below the industry median of 50-60% for stable manufacturing companies, particularly concerning given the rapid deterioration from 80.3% prior year. Current ratio of 74.2% falls well below the 100-150% range typical for healthy industrial companies, signaling liquidity stress. Efficiency: The company's total asset turnover of 1.10x is within the 0.8-1.5x range for manufacturing sectors, but the negative operating margin renders revenue efficiency metrics less meaningful. The elevated CapEx intensity of 17.3% of revenue (versus typical 5-10% for mature manufacturers) indicates growth investment phase, but without positive cash generation from operations. The company's positioning is weak relative to industry norms across profitability, liquidity, and financial health dimensions. The combination of negative operating margins, sub-100% current ratio, and declining equity ratio places the company in the bottom quartile of financial health for its composite industry group. Relative to sector median, the company requires urgent operational restructuring and balance sheet stabilization before it can be considered investment-grade.
Operational turnaround is required: The shift from modest profitability (operating income 0.9B prior year) to severe operating loss (-14.2B) driven by revenue growth in an unprofitable segment (robot business -2.4% margin) indicates fundamental business model execution failure. The SGA expense of 20.0B (99.3% of revenue) including 4.0B goodwill amortization is structurally unsustainable. Excluding the 15.1B non-recurring impairment, the underlying business still generated approximately -15.2B in losses, demonstrating that profitability restoration requires both cost structure rationalization (SGA reduction, overhead optimization) and segment-level profit improvement (particularly converting the 10.2B robot segment revenue to positive margin). The historical trend shows operating margin collapsing from +6.1% to -70.8% in a single period, suggesting execution missteps in scaling the robot business post-acquisition.
Near-term liquidity and capital structure are critical priorities: Cash declining 84.8% to 1.0B combined with current ratio of 74.2%, short-term debt coverage of 0.38x, and 52% short-term liability ratio create immediate refinancing imperative. The negative operating CF of -2.2B and FCF of -6.8B indicate ongoing cash consumption that cannot be sustained beyond the near term without capital raise (equity dilution) or asset sales. The company's ability to access credit markets or refinance existing facilities (short-term loans 0.3B, current portion long-term loans 0.2B) will likely depend on credible operational improvement plans. The equity raise of 1.4B in financing CF suggests management is already pursuing capital injections, but equity ratio declining from 80.3% to 40.2% limits further dilution tolerance. Monitoring quarterly cash burn rate, working capital management, and any asset disposal transactions will be essential to assess going concern viability.
Goodwill overhang and future impairment risk remain material: Despite recognizing 15.1B impairment, goodwill of 19.2B still exceeds total equity of 7.3B by 2.6x and represents 105.5% of total assets, creating substantial downside risk if the robot or semiconductor processing segments (sources of goodwill) continue to underperform. The Commercial Support Robot Segment's -2.4% operating margin and -0.2B operating loss suggest the business case supporting goodwill valuation may not materialize, potentially requiring further write-downs. Any additional impairment would deepen the retained earnings deficit (already -30.5B) and further compress equity, potentially triggering debt covenants or requiring balance sheet recapitalization. The historical pattern of large goodwill balances (19.2B prior year to 19.2B current despite 4.0B amortization implies some addition or reclassification) followed by massive impairment (15.1B) indicates M&A integration challenges or overpayment risk. Investors should view the current goodwill as a latent liability rather than productive asset until segment-level cash flow generation validates the carrying value.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.